TP53 and posterior cortical atrophy: The coexistence of KRAS and TP53 mutations may play a crucial role in PCa pathogenesis and seem to have a negative influence on the treatment outcomes in patients, receiving cytotoxic drugs or anti-EGFR/Akt/mTOR target therapy.